Hormone Therapy Dementia Risk: A Million Women Say the Fear Was Wrong
I hear this fear from women constantly. They want hormone therapy. They need it. Their symptoms are real and disruptive and well within the clinical window for treatment. But they pause because somewhere they read or heard that hormones cause memory loss. In fact, that dementia risk is the reason they hesitate at the very door of treatment that could improve their sleep, their mood, their heart health, and their quality of life for the next 30 years.
A WHO-commissioned meta-analysis published in The Lancet Healthy Longevity on December 22, 2025 has now weighed that fear against data from more than 1 million women. University College London researchers analyzed 15 studies, 10 of which contributed data to the formal meta-analysis, covering over 1 million women past menopause across one randomized controlled trial and nine observational studies. This is the most comprehensive synthesis of evidence on hormone therapy dementia risk completed to date.
The finding: no evidence that hormone therapy either increases or decreases the risk of dementia. Not a marginal finding. Not “more research is needed.” In other words, the data does not support the hormone therapy dementia risk claim that has kept women from treatment for two decades.
Hormone Therapy Dementia Risk: What the Lancet Data Actually Found
The WHO commissioned this review as part of the 2025 update to its guidelines on cognitive decline and dementia risk reduction. That context matters. This was not a quick observational study. It was the most rigorous synthesis the research community has produced on this question, specifically designed to inform global clinical practice.
Researchers included studies that met high methodological standards. Of the 15 studies reviewed, 10 provided sufficient data for inclusion in the meta-analysis. The dataset covered more than 1 million women. The conclusion: hormone therapy use in postmenopausal women showed no statistically meaningful increase or decrease in dementia incidence.
Here’s what that means in clinical terms:
Women who take hormone therapy are not at elevated dementia risk compared to women who do not take it. The fear was wrong. It came from a 2002 WHI substudy that used combination synthetic hormone therapy in women averaging 65 years old, many of whom had not used hormones near menopause onset. Clinicians over-extrapolated that narrow finding into a generation-wide refusal of treatment.
This Lancet analysis draws from a far broader evidence base and finds no signal of harm. That is a meaningful clinical correction.
Where the Fear About Hormones and Memory Loss Came From
Specifically, the WHI substudy that alarmed clinicians, published in 2003, enrolled women 65 and older who began combined synthetic hormone therapy well past the menopausal window. That study reported increased dementia risk. Clinicians cited it widely. Nobody put it in proper context.
The timing issue that matters for cardiovascular risk also matters for brain health. Estrogen has direct neuroprotective effects: it supports mitochondrial function in brain cells, maintains blood-brain barrier integrity, and modulates inflammation that drives Alzheimer’s pathology. Introducing estrogen to a brain that has adapted to low estrogen for years is not the same as maintaining estrogen levels close to the menopausal transition. The 2003 substudy tested the former. Medicine then applied it broadly to the latter. That is the origin of the fear.
What Estrogen Actually Does in the Brain
Additionally, estrogen receptors exist throughout the brain, with particularly high concentrations in the hippocampus, the region central to memory formation. Estrogen supports synaptic plasticity: the process by which neurons form and strengthen the connections that underlie learning and memory. It also plays a role in clearing amyloid protein, the substance that accumulates in Alzheimer’s disease.
So when estrogen drops at menopause, something real happens in the brain. Women often describe it as brain fog: slower word retrieval, difficulty holding complex thoughts, a sense that their processing is less sharp. This is not imagined. It is a measurable cognitive change that accompanies the hormonal transition. The Menopause Society recognizes these cognitive symptoms as a real component of the menopausal experience.
The question of whether hormone therapy prevents Alzheimer’s long-term is still an open research question. The Lancet authors note this limitation directly. What is no longer an open question is whether hormone therapy causes dementia. The answer from 1 million women’s worth of data is no.
Hormone Therapy Dementia Risk: What This Means for Your Decision
If you are in your 50s, in the menopausal window, and hesitating on hormone therapy because of memory concerns, the current evidence does not support that hesitation. The hormone therapy dementia risk you may have read about applies to a specific, outdated study of older women on synthetic hormones. It does not describe your situation.
If you are already experiencing cognitive symptoms during perimenopause, including brain fog, word retrieval difficulty, or difficulty concentrating, those symptoms deserve a full clinical evaluation. Hormones are one piece of the picture. Thyroid function, cortisol patterns, insulin resistance, and sleep quality all affect brain function and all deserve attention in a comprehensive workup.
The key takeaway is not that hormone therapy prevents dementia. The current data does not show that. The key takeaway is that hormone therapy does not cause dementia, and the fear that drove a generation of women away from appropriate treatment lacked grounding in solid evidence.
Key Takeaways
- A WHO-commissioned Lancet Healthy Longevity meta-analysis of 1 million women across 15 studies found no evidence that hormone therapy increases the risk of dementia in postmenopausal women.
- The fear about hormone therapy dementia risk originated from a 2003 WHI substudy of women 65 and older starting synthetic hormones well past the menopausal window. Medicine over-applied that narrow result to all women.
- Estrogen has direct neuroprotective roles in the brain, including support for memory-related synaptic connections and amyloid clearance, but the evidence that hormone therapy prevents Alzheimer’s long-term is still incomplete.
- Brain fog, word retrieval difficulty, and cognitive changes during perimenopause are real and recognized symptoms. They deserve clinical evaluation, not reassurance.
- The current clinical guidance from major organizations supports hormone therapy for symptomatic women under 60 or within 10 years of menopause, and dementia risk is no longer a reason to withhold treatment.
Frequently Asked Questions
Does hormone therapy increase the risk of dementia? No. A December 2025 meta-analysis in The Lancet Healthy Longevity, analyzing data from more than 1 million women across 15 studies and commissioned by the WHO, found no evidence that hormone therapy either increases or decreases dementia risk in postmenopausal women. This comprehensive data does not support the fear about hormone therapy dementia risk.
Why did people think hormone therapy caused memory loss? A 2003 substudy of the Women’s Health Initiative reported increased dementia risk in women 65 and older who began combined synthetic hormone therapy well past the menopausal window. Clinicians applied that finding broadly to all hormone therapy users, including younger women starting treatment close to menopause onset. The Lancet 2025 analysis, which covers a far broader evidence base, does not replicate that signal.
Understanding Estrogen and Brain Health
Does estrogen protect the brain? In fact, estrogen receptors exist throughout the brain, including in the hippocampus, the region central to memory formation. Estrogen supports synaptic plasticity, mitochondrial function in neurons, and blood-brain barrier integrity. Animal research and observational studies suggest neuroprotective effects, particularly when women maintain estrogen levels close to the menopausal transition. Whether hormone therapy prevents Alzheimer’s long-term in humans remains under active investigation.
What causes brain fog during perimenopause? Brain fog during perimenopause reflects a real, measurable cognitive change tied to declining estrogen and the hormonal volatility of the transition. Women report slower word retrieval, difficulty holding complex thoughts, and reduced mental sharpness. Thyroid dysfunction, poor sleep, cortisol dysregulation, and insulin resistance can compound these effects. A comprehensive evaluation looks at all of these contributors, not just estrogen.
Making an Informed Decision About Hormone Therapy and Brain Health
Should I start hormone therapy to protect my brain? In short, current evidence does not support starting hormone therapy solely for dementia prevention. The Lancet study found neutral effects, not protective ones, in the overall analysis. What the data does support is starting hormone therapy for symptomatic relief: hot flashes, sleep disruption, mood changes, and vaginal symptoms. If you are symptomatic and in the appropriate age window, dementia fear should not be the reason you decline treatment.
What should a complete cognitive and hormonal workup include? A comprehensive evaluation for a perimenopausal or postmenopausal woman with cognitive symptoms should include estradiol, FSH, testosterone, and thyroid function. It should also include fasting insulin, cortisol assessment, and inflammatory markers. Sleep quality matters. Doctors often overlook B12, iron, and vitamin D, and all three affect cognition. A full panel gives a complete picture that a single hormone test misses.
Dr. Betty’s Bottom Line
Medicine has denied women appropriate hormone therapy for two decades partly because of a dementia fear that, according to the most comprehensive data ever assembled on this question, the evidence does not support. One million women’s worth of data. Fifteen studies. A WHO-commissioned review. And the conclusion is that hormone therapy does not cause dementia. I have never been satisfied with a medical culture that defaults to withholding treatment from women based on one flawed study’s flawed application.
What I see in my practice is that women who address hormonal and metabolic health comprehensively in their 50s function better in their 60s and 70s. Their cognitive function, their heart health, their bone density, their body composition: these outcomes track together. They are not independent. When you treat the root cause and maintain hormonal and metabolic optimization, the body’s systems support each other. That is functional medicine’s contribution to the dementia conversation.
The question is not just whether hormones cause dementia. The question is: what does a comprehensive, personalized approach to midlife health do for your brain over the long term? That is the question worth asking.
In-person care at Living Well Dallas is available for patients in the Dallas area. Menrva Health offers comprehensive hormonal and cognitive health evaluation through telehealth in all 50 states.
Source: Melville M, Spector A, et al. Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis. Lancet Healthy Longev. 2025 Dec 22. doi:10.1016/S2666-7568(25)00122-9